Gotham Makker - 18 Jun 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Director
Issuer ticker: RCKT
Reported as of: 18 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jul 2025, 16:05:40 UTC
Prior SEC filing: 29 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for Gotham Makker

Key filing fact

Gotham Makker filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 18 Jul 2025.

Key facts

This page summarizes Gotham Makker's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Jul 2025, 16:05.

Change

Previous filing in this sequence was filed on 29 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001726391 Primary reporting owner

Makker Gotham

Relationship: Director
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for Gotham Makker
Signature date: 18 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Common Stock

Award

Transaction value: $0
Shares: +30,000
Change %: +8.2%
Price: $0.000000
Shares after: 395,912
Date: 18 Jun 2025
Ownership: By Simran Investment Group
Footnotes: F1, F2

RCKT transaction

Common Stock

Award

Transaction value: $0
Shares: +19,434
Change %: +4.9%
Price: $0.000000
Shares after: 415,346
Date: 18 Jun 2025
Ownership: By Simran Investment Group
Footnotes: F1, F2, F3

RCKT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 621,500
Date: 18 Jun 2025
Ownership: By Non-Revocable Trust
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.

Footnote F2

Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $55,000. The RSUs will vest in full on June 18, 2026.

Footnote F3

The securities may be deemed beneficially owned by Gotham Makker, M.D., who serves as the Chief Executive Officer and Chief Investment Officer of Simran Investment Group and who is a director of the Issuer. Dr. Makker exercises voting and dispositive control over the securities held by Simran Investment Group and is therefore deemed be the beneficial owner of securities owned or controlled by Simran Investment Group. Notwithstanding the foregoing, Dr. Makker disclaims personal beneficial ownership of the reported securities held by Simran Investment Group, except to the extent of his pecuniary interest therein.

Footnote F4

The securities may be deemed to be beneficially owned by the reporting person and are held by a non-revocable trust for the benefit of the reporting person's children. The reporting person has no voting or investment power over all securities owned by the trust.